[Question] how do you actually verify Zepbound
how do you actually verify Zepbound. I am not trying to be the "source?" guy. I would just like a source.
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
On comparing yourself with the trial number.
SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.
Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
SURMOUNT-1 landed around 21% at 72 weeks on the top arm
dual agonist, so the GIP arm is doing something the sema threads will not tell you about
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
the reflux profile is genuinely gentler than people expect coming from sema
zepbound and mounjaro are the same compound with different labels
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.
Which week did the appetite change actually land for you?
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
What is the waist doing? That is usually the number still moving during a scale stall.
the four-week step schedule is the label, not folklore
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.
Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.
Correction to my own post above — I said 10mg and I have been on 12.5mg since the spring. Same argument, wrong number.
the trials titrated on a calendar, real people titrate on symptoms
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
if 7.5 is working, 10 is not automatically better
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
sulphur burps are the signature complaint and they are not dangerous
18kg over 83 weeks, never went past 10mg, and muscle cramps stayed mild the whole way. Posting because the loud threads are all 15mg.
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.
Pen or vial? The step sizes available differ and it changes this answer.
- 1the reflux profile is genuinely gentler than people expect coming from sema8 comments in this branch · started by u/tove_vasquez
- 2The distribution matters more than the mean. In the trial population the…6 comments in this branch · started by u/signe_villalobos